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Summary
Background Patients with actinic keratosis (AK) are at increased risk for developing
keratinocyte carcinoma (KC) but predictive factors and their risk rates are
unknown.
Objectives To develop and internally validate a prediction model to calculate the
absolute risk of a first KC in patients with AK.
Methods The risk-prediction model was based on the prospective population-based
Rotterdam Study cohort. We hereto analysed the data of participants with at least
one AK lesion at cohort baseline using a multivariable Cox proportional hazards
model and included 13 a priori defined candidate predictor variables considering
phenotypic, genetic and lifestyle risk factors. KCs were identified by linkage of
the data with the Dutch Pathology Registry.
Results Of the 1169 AK participants at baseline, 176 (151%) developed a KC after
a median follow-up of 18 years. The final model with significant predictors was
obtained after backward stepwise selection and comprised the presence of four to
nine AKs [hazard ratio (HR) 168, 95% confidence interval (CI) 117–242], 10
or more AKs (HR 244, 95% CI 165–361), AK localization on the upper
extremities (HR 075, 95% CI 052–108) or elsewhere except the head (HR
140, 95% CI 098–201) and coffee consumption (HR 092, 95% CI 084–
101). Evaluation of the discriminative ability of the model showed a bootstrap
validated concordance index (c-index) of 060.
Conclusions We showed that the risk of KC in patients with AK can be calculated
with the use of four easily assessable predictor variables. Given the c-index,
extension of the model with additional, currently unknown predictor variables is
desirable.
What’s already known about this topic?
• Patients with actinic keratosis (AK) are at increased risk of developing keratinocyte
carcinoma (KC), including both squamous cell and basal cell carcinoma.
• However, risk rates and predictive factors are unknown and to date no risk-predic-
tion model has been developed for patients with AK.
What does this study add?
• We present a multivariable risk-prediction model with an additional tool to calcu-
late the absolute risk of KC development in patients with AK.
• The number of AKs (4–9 or ≥ 10), location of AKs (upper extremity or elsewhere
except head) and coffee consumption are significant predictors with a moderate
discriminative ability.
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• This prediction model may help in the management of patients with AK but exten-
sion with additional factors is desirable before clinical implementation.
Actinic keratoses (AKs) are premalignant lesions and can be
considered a clinical biomarker for cutaneous photodamage.1
Population-based studies report a high prevalence of AKs,
especially in elderly people of European ancestry.2,3 In the
Netherlands, 235% of the population aged 50 years or older
has one or multiple AKs.4 Individual AKs may progress into
cutaneous squamous cell carcinoma (cSCC). Additionally, as a
marker of ultraviolet radiation (UVR)-induced DNA damage,
the presence of AK is a risk factor for keratinocyte carcinoma
(KC) in general, including basal cell carcinoma (BCC).5–7 It is
unclear which patients with AK will develop KCs and how
high this risk rate is, although several AK characteristics such
as the presence of multiple AKs and their anatomical site, as
well as general phenotypic factors (e.g. light pigment status)
and exposure-related items (e.g. high UVR exposure) have
been described to increase progression risk.8–10 Correctly
identifying high-risk patients is important to detect KCs at an
early stage and to ensure timely intervention. Moreover, strati-
fied AK management may reduce patients’ anxiety, provide
better management for high-risk individuals, and optimize the
use of healthcare resources.11
Until now, several KC prediction models have been devel-
oped regarding the occurrence of either a first or subsequent
KC in the general population.12–15 However, none of these
assessed what factors predict a KC in an AK population, which
is a very relevant question for many healthcare providers. We
therefore aimed to develop a model to predict the absolute
risk of a first KC in patients with AK, taking into account phe-
notypic, genetic and lifestyle risk factors, by analysing over
1000 participants with AK from the prospective population-
based Rotterdam Study cohort (RS).
Patients and methods
Study population
The RS is a prospective population-based cohort study com-
prising 14 926 participants aged 45 years and older from the
general population of Ommoord in Rotterdam, the Nether-
lands. From July 1989 to present, the participants have under-
gone regular examinations in a research facility and interviews
are conducted at home about every 3–4 years. Between 2010
and 2016, complete skin examinations were performed during
the RS routine, focusing on common skin diseases including
AK as well as potential risk factors. We included participants
with at least one AK lesion during one of these examinations
in our model. The date of first AK diagnosis in the RS cohort
served as the starting point of follow-up.
The RS has been approved by the Medical Ethics Committee
of the Erasmus MC (registration number MEC 021015) and
by the Dutch Ministry of Health, Welfare and Sport (Popula-
tion Screening Act WBO, license number 1071272-159521-
PG). All participants provided written informed consent to
participate in the study and to have their information obtained
from treating physicians. Details of the study design and
objectives have been described before.16
Case definition
The study outcome was defined as a first KC, either BCC or
cSCC, after AK diagnosis. To identify all cases of KC, the RS
participants were linked to the Dutch nationwide network and
registry of histo- and cytopathology in the Netherlands
(PALGA) using encrypted patient data [combination of the
patient’s sex, birth date and first four to eight letters of the
(maiden) family name]. Participants with a BCC or cSCC diag-
nosis prior to their AK diagnosis were excluded, as our study
was focused on KC-na€ıve patients with AK. Follow-up of all
participants ended at the time of KC diagnosis or, when this
outcome measure was not met, at the date of censoring. Cen-
soring events were death as assessed from the municipal regis-
ter or end of available PALGA follow-up on 31 July 2018,
whichever occurred first.
Candidate predictor variables
The candidate predictor variables were selected a priori based on
literature review and clinical expertise and were categorized as
follows: AK-specific variables, phenotypic factors, lifestyle factors,
UVR exposure variables and a genetic susceptibility variable.
As AK-specific variables, we included the number of AKs at
diagnosis8,9,14,17–21 (prespecified into 1–3, 4–9, ≥ 10 during
skin examinations) and categorized the location of AKs into
three main groups: head, upper extremities and elsewhere. In
the case of AKs on multiple locations per participant, more
than one location variable could be selected.
We included four phenotypic factors, namely age at AK
diagnosis in the RS (years),12–14,17,22,23 sex,12–14,17,18,22 ten-
dency to develop sunburn8,12–14,17,20,24,25 and pigment sta-
tus.8,18,24,26 The latter constituted a combination of hair and
eye colour when young, as reported previously.13
As lifestyle factors, smoking (never vs. current or
ever)8,14,27,28 and coffee consumption (cups per
day)12,13,29,30 were included. Regarding UVR exposure, we
selected variables reflecting intermittent or chronic exposure
to UVR. Intermittent UVR exposure8,20,23,31,32 was defined as
a combination of likeliness to be outdoors when the sun is
shining/having mainly outside hobbies, going on holidays to
a sunny country at least 4 weeks per year and sunbed usage
of at least 10 times in the past 5 years. Chronic UVR
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exposure8,17,18,20,26,27,33 was assessed as the history of occu-
pational outdoor work for at least 4 h per day during at least
25 years.
We calculated a genetic risk score (GRS) per patient with
AK by retrieving seven single-nucleotide polymorphisms
(SNPs) that were significantly associated with both BCC and
cSCC occurrence from the most recent genome-wide associa-
tion studies (Tables S1 and S2; see Supporting Informa-
tion).34,35 A detailed description of the GRS computation
method is presented in Appendix S1 (see Supporting Informa-
tion). In brief, a weighted GRS was calculated using the
regression coefficients of published associations between the
selected SNP and cSCC, which were similar for BCC.35 The
genetic scores were computed as follows: GRS = ΣbiGi; where
bi is the log(odds ratio) of the SNP and Gi is the number of
per SNP risk alleles (0, 1 or 2).
All predictor variables were measured at baseline, i.e. at the
moment of AK diagnosis, DNA from whole blood was
extracted at the start of each cohort (I–III) within RS. For life-
style and UVR exposure variables, values from an earlier
examination round were used if they were missing at base-
line.
Model development and performance
We used a Cox proportional hazards model to determine the
probability of first KC development in patients with AK, taking
censoring into account. Before starting the model develop-
ment, collinearity among plausible categorical predictor vari-
ables was tested with Cramer’s V statistic with no evidence
found for multicollinearity. We imputed all missing predictor
variables except for GRS 10 times using multivariate imputa-
tion by chained equations,36 under the assumption that the
data were missing at random. We included all candidate pre-
dictors, the outcome (KC or censored) and the follow-up time
in years in the imputation model. Also, RS cohort number (I–
III) and socioeconomic status of the participants were included
as auxiliary variables.
Univariable analyses were performed for all candidate pre-
dictor variables and the occurrence of KC. For the continuous
variables age and coffee consumption, we explored a possible
nonlinear relationship using a natural cubic spline with two
degrees of freedom. The use of a spline for these variables
neither significantly improved the fit of our model (measured
with the 92 value) nor provided graphical evidence for a non-
linear relationship. We therefore included these variables in
their linear forms.
Regardless of their P-values in the univariable analyses, all
candidate predictors were included in the multivariable
model.37,38 We reduced the multivariable model by backward
stepwise selection using a two-sided statistical significance
level of a = 020 as the cutoff point to reduce selection bias
and optimism and to prevent the exclusion of important pre-
dictors.38 The estimated regression coefficients and variances
from the 10 imputed datasets were combined based on
Rubin’s rules.39
We assessed the predictive performance of our model in terms
of discrimination using Harrell’s concordance index (c-index).
The c-index in survival context can be interpreted as the probabil-
ity that the model assigns a higher predicted risk of KC develop-
ment to a patient (from a randomly chosen pair of patients) that
develops KC earlier in time compared with a patient developing
KC later in time and varies from 05 (noninformative model) to
10 (perfect model).40 As a means of internal validation, boot-
strapping was used to correct the c-index for optimism.
To account for overfitting, we multiplied the regression
coefficients from our final model with a shrinkage factor,
which we estimated with bootstrapping (1000 replications).
Shrinkage of regression coefficients towards average is meant
to improve predictions in future patients by preventing
extreme distributions of the predictions.38
A complete case analysis was performed as sensitivity analy-
sis. Reporting of the model is done according to the TRIPOD
statement.41
Model presentation
To provide individualized predictions on the risk of first KC
development in patients with AK, we made a risk-prediction
tool based on the shrunk regression coefficients of our inter-
nally validated model using Microsoft Excel (2010).
Descriptive statistics were computed using IBM SPSS Statis-
tics for Windows, version 240. (IBM Corp.; Armonk, NY,
USA). Model development and internal validation were con-
ducted using R statistical software version 350 (R Foundation
for Statistical Computing; Vienna, Austria) with the mice,
Hmisc and rms libraries.
Results
Study population
A selection of all participants with at least one AK lesion at
baseline resulted in 1558 participants. After linkage with
PALGA, 389 participants were excluded who had at least one
KC prior to their AK diagnosis. The median follow-up of the
remaining 1169 participants was 52 years [interquartile range
(IQR) 35–69], during which 176 participants developed a
KC at a median follow-up of 18 years (IQR 02–38). The
majority of participants (589%) had one to three AK lesions
at baseline, mainly located on the head (844%). The overall
median age was 730 years (IQR 670–800) and 55% of all
participants were men (Table 1).
Predictors for a first keratinocyte carcinoma
In univariable analyses, the presence of four to nine AKs and 10
or more AKs, an AK localization outside the head or upper
extremities and increasing age were significantly associated with
a higher risk of KC development (Table 2). On the contrary,
the risk of KC occurrence decreased per cup of coffee consump-
tion [hazard ratio (HR) 092, 95% confidence interval (CI)
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084–101]. After backward stepwise selection, four predictor
variables remained in the final model: number of AKs at diagno-
sis (either 4–9 or 10 or more), localization of AKs on the upper
extremities, localization of AKs elsewhere except on the head,
and coffee consumption. After adjustment for all other predic-
tors in multivariable analysis, age was not significantly associ-
ated with KC anymore. Having 10 or more AKs was the
strongest predictor with an almost 25 times higher hazard of
KC development compared with the presence of one to three
AKs (HR 244, 95% CI 165–361). Although evidence exists
for a familial aggregation basis of skin cancer,34,35,42–44 the GRS
based on SNPs associated with KC did not increase the risk of
KC development in our AK population.
A sensitivity analysis on 335 participants with no missing
values yielded comparable HRs but without the AK location
variables in the reduced multivariable model (Table S3; see
Supporting Information). The overall apparent c-index of
the final model was 061 (95% CI 056–066). After inter-
nal validation of the model with bootstrapping, the opti-
mism corrected c-index reduced to 060 (95% CI 057–
066).
Model presentation
Figure 1 shows an image of the risk-prediction tool that can
be used easily to predict an AK patient’s risk of KC
Table 1 Descriptive characteristics of the 1169 participants with at least one actinic keratosis (AK) at baseline and cases of keratinocyte carcinoma
(KC) (N = 176) separately
Candidate predictor variables Category Overall (N = 1169) KC cases (N = 176) Non-KC group (N = 993)
Number of participants 1169 (100%) 176 (151%) 993 (849%)
Follow-up time (years) Median (IQR); (range) 52 (35–69); (00–79) 18 (02–38); (03–79) 57 (37–70); (00–73)
Age at AK diagnosis (years) Median (IQR) 730 (670–800) 730 (670–790) 730 (670–800)
Sex Male 643 (550%) 96 (545%) 547 (551%)
Number of AKs at diagnosis 1–3 689 (589%) 78 (443%) 611 (615%)
4–9 290 (248%) 49 (278%) 241 (243%)
≥ 10 190 (163%) 49 (278%) 141 (142%)
AK on the heada No 182 (156%) 26 (148%) 156 (157%)
Yes 987 (844%) 150 (852%) 837 (843%)
AK on upper extremitiesb No 882 (754%) 132 (750%) 750 (755%)
Yes 287 (246%) 44 (250%) 243 (245%)
AK on other locationsc No 973 (832%) 132 (750%) 841 (847%)
Yes 196 (168%) 44 (250%) 152 (153%)
Pigment statusd Dark 222 (190%) 32 (182%) 190 (191%)
Intermediate 618 (529%) 95 (540%) 523 (527%)
Light 281 (240%) 43 (244%) 238 (240%)
Missing 48 (41%) 6 (34%) 42 (42%)
Being easily sunburned No 704 (602%) 100 (568%) 604 (608%)
Yes 416 (356%) 69 (392%) 347 (349%)
Missing 49 (42%) 7 (40%) 42 (42%)
Intermittent sun exposuree No 114 (98%) 18 (102%) 96 (97%)
Yes 732 (626%) 97 (551%) 635 (639%)
Missing 323 (276%) 61 (347%) 262 (264%)
Outdoor workf No 462 (395%) 74 (420%) 388 (391%)
Yes 133 (114%) 20 (114%) 113 (114%)
Missing 574 (491%) 82 (466%) 492 (495%)
Smoking Never 357 (305%) 50 (284%) 307 (309%)
Current or ever 798 (683%) 123 (699%) 675 (680%)
Missing 14 (12%) 3 (17%) 11 (11%)
Coffee consumption (cups/day) Median (IQR) 33 (14–33) 14 (14–33) 33 (14–33)
Missing 131 (112%) 23 (131%) 108 (109%)
GRS Median (IQR) 10 (10–11) 11 (10–11) 10 (10–11)
Missing 159 (136%) 25 (142%) 134 (135%)
GRS, genetic risk score; IQR, interquartile range. aPresence of AK on the face, ears and/or scalp. bPresence of AK on the back of the hands
and/or forearms. cPresence of AK on locations elsewhere (not specified). dA combination of hair and eye colour when young. eCombination
variable of a confirmatory answer to one or more of the following questions:
• Are you likely to be outside when the sun is shining/do you mainly have outside hobbies?
• Do you go on holidays to a sunny country at least 4 weeks per year on average?
• Have you used a sunbed for at least 10 times during the past 5 years?
fTo have been/worked outdoors for at least 4 h daily during at least 25 years.
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development, given the four prognostic factors from the final
model. The regression coefficients of these predictors have
been multiplied with an estimated shrinkage factor of 091.
After filling in the individual values for each of these predic-
tors, the tool calculates the percentage risk of a first KC in 1,
3 and 5 years. For example, a patient with 10 AKs spread over
the upper extremity and other body sites except the head and
who drinks three cups of coffee per day, has a 23% risk of KC
development in 5 years. Formula File S1, an Excel spreadsheet
containing this risk-prediction tool, is available for reference
in the online Supporting Information.
Discussion
Our population-based study with over 1000 participants pro-
vides the first risk-prediction model for an AK-specific patient
group and encompasses readily available phenotypic, lifestyle,
UVR and genetic KC susceptibility factors. The strongest pre-
dictor of a first KC was having 10 or more AKs at diagnosis,
which increased the KC risk by almost 25-fold. This is in line
with other cohort studies demonstrating a strong dose–re-
sponse relationship between the number of AKs and the risk
of a KC.9,19–21 This finding could be explained through several
theories. Firstly, cumulative UVR exposure underlies both AK
and KC development. A study of the association between AKs
and KCs showed that the aetiological factors for AK develop-
ment were essentially equal to the aetiological factors for both
BCC and cSCC development.17 Secondly, AKs can be seen as
an early phase in the biological continuum that eventually cul-
minates in cSCC, which means that some of the AKs in our
cohort might have progressed directly to cSCC.21 Thirdly,
from the concept of field cancerization, the presence of multi-
ple AKs forms the ultimate groundwork for the progression of
epithelial carcinogenesis.45
Little is known about the risk of KC development based on
AK affected body site. We found that AKs localized on the
upper extremities significantly decreased and AKs localized
outside the head and upper extremities significantly increased
the risk of KC. This finding is consistent with a Dutch system-
atic review concluding that patients with AKs on the head or
upper extremity regions are less likely to develop KCs com-
pared with patients with AKs on the neck, trunk or lower
extremities.46 An explanation for our finding is not straight-
forward. It is remarkable that covered body sites showed
higher risk rates than the more chronic sun-exposed head and
upper extremity regions, which may hint to a different car-
cinogenesis pattern than chronic UVR exposure.
Coffee consumption is a much-discussed factor in the field
of skin cancer carcinogenesis. In our analyses, we found that
coffee consumption significantly reduced the risk of a first KC
by 8% per cup of coffee. Findings from mainly laboratory and
animal studies have indicated a possible protective effect of
caffeine against KC development through induction of apopto-
sis in UVR-damaged keratinocytes as well as inhibition of
Table 2 Associations [hazard ratios (HRs) with confidence intervals (CIs)] between candidate predictor variables and development of a first KC (n
= 176) using a Cox proportional hazards model
Candidate predictor variables Coding Univariable HR (95% CI) Multivariable HRa (95% CI)
Age 101 (099–103)* –
Sex Female 103 (077–139) –
Number of AKs at diagnosis 1–3 Reference Reference
4–9 159 (111–228)** 168 (117–242)**
≥ 10 247 (173–353)*** 244 (165–361)***
AK on the headb Yes 109 (072–165) –
AK on upper extremitiesc Yes 099 (071–141) 075 (052–108)*
AK on other locationsd Yes 172 (123–243)*** 140 (098–201)*
Pigment statuse Dark Reference –
Intermediate 101 (068–151)
Light 100 (063–157)
Being easily sunburned Yes 111 (082–151) –
Intermittent sun exposuref Yes 084 (052–136) –
Outdoor workg Yes 093 (058–151) –
Smoking Ever 109 (078–151) –
Coffee consumption (cups/day) 092 (084–101)* 092 (084–101)*
GRS 192 (058–631) –
AK, actinic keratosis; GRS, genetic risk score. *P-value < 020, **P-value < 005, and ***P-value < 0005. aFinal model after backward step-
wise selection. bPresence of AK on the face, ears and/or scalp. cPresence of AK on the back of the hands and/or forearms. dPresence of AK
on locations elsewhere (not specified).
eA combination of hair and eye colour when young. fCombination variable of a confirmatory answer to one or more of the following ques-
tions: • Are you likely to be outside when the sun is shining/do you mainly have outside hobbies?
• Do you go on holidays to a sunny country at least 4 weeks per year on average?
• Have you used a sunbed for at least 10 times during the past 5 years?
gTo have been/worked outdoors for at least 4 h daily during at least 25 years.
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UVR-induced carcinogenesis.47–49 The chemo-protective effect
of caffeine for KC (especially for BCC) in European-descent
populations has recently been supported by two meta-analyses
of observational studies as well.29,30 Furthermore, the relation
between coffee consumption and other malignancies has been
investigated intensively: a significantly lower risk of cancers
of, for example, the liver, endometrium, oral cavity and phar-
ynx has been found.50–54 Also, in these malignancies, the
chemical and biological properties of coffee are mainly cited
as the inducers of its positive effect. Additionally, we believe
that coffee intake can be considered a proxy for good health
and wellbeing as consumers of coffee often have a healthier
lifestyle in general and therefore a lower risk of various malig-
nancies, as argued by a recent review.55 Focusing on the KC
outcome, one could also hypothesize that people who drink
more coffee are more often engaged in office jobs while peo-
ple that rarely drink coffee are the ones involved in occupa-
tional outdoor work. This would result in a higher UVR
exposure in the latter group and hence a higher KC risk, a
potential effect which we were unable to adjust for (residual
confounding).
Remarkably, none of the UVR-related predictor variables
nor participants’ pigment status was associated with KC. This
is in line with other KC prediction models that used the same
or comparable sun-exposure variables.7,13–15 Because we
selected our study population on the presence of AKs, which
in a way can be considered primary KCs because of equal risk
profiles, index-event bias may underlie the results: UVR expo-
sure is a pivotal risk factor for the occurrence of AKs, but in
our model paradoxically not for a subsequent KC.56 This is
because conditioning on the presence of AKs generates depen-
dence between all other known and unknown risk factors,
eventually leading to underestimated or even reversed effects
and biasing the risk rates towards the null. We indeed found
HRs that were low (for being easily sunburned) or even
seemed to be protective (history of outdoor work and inter-
mittent sun exposure) in our univariable analyses, which are
likely to be caused by index-event bias.
Regarding limitations, with the current internally validated
discriminative value, our risk-stratification tool might not be
clinically useful yet. Although we were able to include all vari-
ables of interest as derived from literature and clinical exper-
tise, we found a c-index of 060. This poor-to-moderate c-
index could be explained by the very homogeneous nature of
our study population, which is an important distinction with
prior models that were developed in a general population.14,15
Patients with AK are a priori people with fair skin, at advanced
age, and who have all had cumulative UVR exposure through-
out the years. Finding additional KC predictors that specifically
discriminate within the AK population is therefore a challeng-
ing task and the phenotypic, lifestyle and genetic risk factors
at hand appeared to be insufficient. Another explanation for
the moderate c-index might be that we have not separated
BCC and cSCC as separate outcome measures due to insuffi-
cient power. Effect estimates per predictor could differ for
BCC and cSCC, thereby influencing the discriminative ability
of our model. However, a quick subgroup check on univari-
able analyses between the predictors and BCC/cSCC separately
did not show any differences between both KC types (data
not shown). Still, given the very limited existing knowledge
in the AK prognostic field, we believe that the current model
provides important insights and can be used to build on for
more extensive models and the selection of tailored variables.
Another limitation is that we assessed only the number of AKs
at the moment of diagnosis during the RS, while this could
have fluctuated during follow-up due to, for example, treat-
ment or spontaneous regression of the lesion. Also, the num-
ber of AKs was already prespecified into the three categories
during the skin examinations and we therefore could not
include AK as a continuous variable in our model. However,
as we assessed the overall risk of KC development considering
all AKs in a patient instead of the lesion-specific progression
risk, we do not expect that potential slight changes in the
number of AKs would have affected the risk rates or the c-
index of our model. Lastly, when interpreting our findings,
one has to keep in mind that the study population comprised
only people aged 45 years or older. Although AKs and KCs are
mostly prevalent in the elderly population, this age criterion
might limit the generalizability of our results. We have tried
to find an independent cohort for external validation of our
prediction model (QSkin Sun and Health Study from Aus-
tralia).57 Unfortunately, detailed information on AKs and other
predictors from our model was not available.
Predictors Value
Number of AKs 10
AK upper extremity yes/no 1
AK elsewhere (except head) yes/no 1
Coﬀee consumpon cups/day 3
Predicted probability of first KC development
1 year 10%
3 year 16%
5 year 23%
Fig 1. Risk-prediction tool for KC development in patients with AK,
filled in for an example patient with 10 AKs, located on the upper
extremity and elsewhere (not on the head), and who drinks three cups
of coffee per day. The subsequent formula is used to predict the
percentage risk of a first KC at 1 year after AK diagnosis: P = [1–(EXP(–
EXP(lp–lp.centered)*baselinehaz))] 9 100% where lp = –0278*AK
location upper extremity + 0345*AK location elsewhere except head –
0060*cups of coffee per day + presence of multiple AKs (0 if 1–3 AKs,
0515 if 4–9 AKs, 0888 if ≥ 10 AKs), lp.centered = 0104 and the
baseline hazard is 0057. Both lp and lp.centered have been multiplied
by the shrinkage factor of 091. For the risks at 3 and 5 years, the
baseline hazard should be replaced by 0092 and 0144, respectively.
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In conclusion, the risk of first KC development in patients
with AK can be predicted by a simple tool including the num-
ber and two location sites of AKs along with coffee consump-
tion. This information can help physicians in identifying
patients at high risk of KC and in planning further AK man-
agement. Extension with additional predictive factors and
external validation thereafter are needed before use in clinical
practice is recommended.
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